Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1552-1561

  Graat, Harm C A ^a   Carette, Jan E ^a   Schagen, Frederik H E ^a   Vassilev, Lyubomir T ^b   Gerritsen, Winald R ^a   Kaspers, Gertjan J L ^a   Wuisman, Paul I J M ^a   Van Beusechem, Victor W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; NUTLIN; ONCOLYTIC ADENOVIRUS; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; EWING SARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGENY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, REPORTER; GENOTYPE; HUMANS; IMIDAZOLES; NEOPLASMS; ONCOLYTIC VIRUSES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250736349     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0631     Document Type: Article

References (30)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
2. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
3. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
5. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
7. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-9.
8. Polsky D, Bastian BC, Hazan C, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001;61:7642-6.
9. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002;21:2750-61.
10. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8:S38-42.
11. Klein C, Vassilev LT. Targeting the p53-2 interaction to treat cancer. Br J Cancer 2004;91:1415-9.
12. Chene P. Inhibiting the p53-2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3:102-9.
13. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
14. Lane D. Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy. Carcinogenesis 2004;25:1077-81.
15. Tang HJ, Qian D, Sondak VK, Stachura S, Lin J. A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Br J Cancer 2004;90:1285-92.
16. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003;14:933-46.
17. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-71.
18. van Beusechem VW, van den Doel PB, Gerritsen WR. Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther 2005;4:1013-8.
19. Ameyar M, Shatrov V, Bouquet C, et al. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999;18:5464-72.
20. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
21. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006;21:307-15.
22. Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004;279:7598-605.
23. Geoerger B, Vassal G, Opolon P, et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdΔ24-53 against human malignant glioma. Cancer Res 2004;64:5753-9.
24. Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005;24:7673-85.
25. Lomonosova E, Subramanian T, Chinnadurai G. Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1-19K. Oncogene 2005;24:6796-808.
26. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998;4:1068-72.
27. Sauthoff H, Pipiya T, Heitner S, et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002;13:1859-71.
28. Li Z, Day CP, Yang JY, et al. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 2004;64:9080-5.
29. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-76.
30. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000;275:16202-12.